Cargando…
Outcomes of COVID-19 in people with multiple sclerosis treated with cladribine tablets: an update
BACKGROUND: The COVID-19 pandemic is a concern for people with multiple sclerosis (pwMS), especially those receiving disease-modifying therapies. METHODS: We previously summarized outcomes for 46 pwMS treated with cladribine tablets (CladT) and confirmed or suspected COVID-19, as reported to the Mer...
Autores principales: | Jack, Dominic, Damian, Doris, Nolting, Axel, Galazka, Andrew |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier B.V.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8250632/ http://dx.doi.org/10.1016/j.msard.2021.102996 |
Ejemplares similares
-
COVID-19 in patients with multiple sclerosis treated with cladribine tablets: An update
por: Jack, Dominic, et al.
Publicado: (2021) -
Risk factors for COVID-19 infection in patients with multiple sclerosis: a nested case–control study
por: Uhr, Lauren, et al.
Publicado: (2021) -
Is natalizumab a safe treatment for patients with multiple sclerosis in the COVID-19 pandemic? Data from the first year of the pandemic
por: Díaz-Díaz, Judit, et al.
Publicado: (2021) -
Favorable outcomes after COVID-19 infection in multiple sclerosis patients treated with cladribine tablets
por: Jack, Dominic, et al.
Publicado: (2020) -
Integrated Lymphopenia Analysis in Younger and Older Patients With Multiple Sclerosis Treated With Cladribine Tablets
por: Giovannoni, Gavin, et al.
Publicado: (2021)